为探究 Sunitinib 对胃肠道间质瘤（GISTs）细胞衰老的影响，研究人员开展相关研究。结果发现 Sunitinib 可降低 GIST-882 细胞活力、诱导细胞衰老，机制与抑制 SIRT1 有关。这为 GISTs 治疗提供新策略，有望推动该领域发展。 Sunitinib（舒尼替尼）通过抑制 SIRT1（沉默信息 ...

Sunitinib (Sutent; Pfizer), a novel oral multitargeted tyrosine kinase receptor inhibitor blocks the activation of VEGFRs 1–3, PDGFRα, PDGFRβ, KIT, fms-related tyrosine kinase 3 (FLT3), RET ...

Plasma exposure of sunitinib shows large inter-individual variation. Therefore, a pharmacokinetic (PK) study was performed to determine safety and feasibility of sunitinib dosing based on PK levels.

Sunitinib, a vascular endothelial growth factor pathway inhibitor, is an effective treatment for metastatic renal-cell carcinoma. We sought to determine the efficacy and safety of sunitinib in ...

Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study. This is an ...

The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. We conducted a multinational ...

Randomized Multicenter Phase II Trial Comparing Two Schedules of Etirinotecan Pegol (NKTR-102) in Women With Recurrent Platinum-Resistant/Refractory Epithelial ...

Please provide your email address to receive an email when new articles are posted on . The FDA’s Oncologic Drugs Advisory committee voted 8-2 today in support of the use of Pfizer’s sunitinib ...

The clinical trial results of the first-ever head-to-head comparison of the first-line treatments for metastatic renal cell carcinoma (RCC) are published in this week's New England Journal of ...

The appraisal committee reviewed the data available on the clinical and cost effectiveness of sunitinib for the treatment of GIST, having considered evidence on the nature of the condition and the ...

A number of attempts at treating SCLC with targeted therapies have failed, but now there is a glimmer of hope, with positive results from a phase 2 clinical trial with sunitinib (Sutent ...

The Assessment Group and manufacturer identified evidence on the clinical effectiveness of sunitinib as a first-line treatment within its licensed indications against relevant comparators. The ...